Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL A HARTLEY

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1417911587
CMS profile
154543
Location
UNIONTOWN, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,894.42

129 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,894.42 129

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL A HARTLEY

NPI 1417911587 · CMS profile ID 154543

Allopathic & Osteopathic Physicians / Internal Medicine

UNIONTOWN, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417911587?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL A HARTLEY, NPI 1417911587, CMS profile ID 154543. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417911587?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). PAUL A HARTLEY, NPI 1417911587, CMS profile ID 154543. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417911587?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
PAUL A HARTLEY, NPI 1417911587, CMS profile ID 154543, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1417911587?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

129 matching records · $1,894.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 129 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 129.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $15.4307/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832725759 CMS
BOSTON SCIENTIFIC CORPORATION $40.3307/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793761903 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.4007/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850110415 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.7907/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763784898 CMS
Janssen Pharmaceuticals, Inc $9.5007/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788215969 CMS
SANOFI-AVENTIS U.S. LLC $12.3007/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843458925 CMS
PFIZER INC. $13.6507/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832777801 CMS
GlaxoSmithKline, LLC. $12.0506/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803110581 CMS
Janssen Pharmaceuticals, Inc $0.4506/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788215983 CMS
Novo Nordisk Inc $13.3406/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811182697 CMS
PFIZER INC. $15.7206/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833403733 CMS
SANOFI-AVENTIS U.S. LLC $12.8406/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843458921 CMS
Novo Nordisk Inc $16.8306/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811182692 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $11.8506/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850222077 CMS
PFIZER INC. $17.0306/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832582725 CMS
Novo Nordisk Inc $14.1506/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811698611 CMS
Janssen Pharmaceuticals, Inc $13.7206/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788215953 CMS
AbbVie Inc. $18.1505/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794763761 CMS
Novo Nordisk Inc $15.9005/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811596377 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.4605/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850370963 CMS
GlaxoSmithKline, LLC. $21.0905/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802139555 CMS
Amgen Inc. $19.0205/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826408731 CMS
Lilly USA, LLC $18.1805/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818685917 CMS
Amarin Pharma Inc. $14.5605/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815281795 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $15.9305/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851918241 CMS
DEXCOM, INC. $11.7005/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845280355 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.4105/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763784900 CMS
GlaxoSmithKline, LLC. $20.7105/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802107187 CMS
Janssen Pharmaceuticals, Inc $11.1905/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788215977 CMS
Astellas Pharma US Inc $23.6905/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821356319 CMS
Novo Nordisk Inc $17.9504/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810799775 CMS
SANOFI-AVENTIS U.S. LLC $12.3804/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843458903 CMS
SANOFI-AVENTIS U.S. LLC $11.9704/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843458913 CMS
PFIZER INC. $22.2104/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832550157 CMS
Novo Nordisk Inc $16.4304/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811596374 CMS
Lilly USA, LLC $14.5404/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818720199 CMS
PFIZER INC. $9.4604/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833459495 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.0104/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763784902 CMS
Janssen Pharmaceuticals, Inc $14.8504/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788215979 CMS
PFIZER INC. $16.3704/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833407163 CMS
Radius Health, Inc. $18.9404/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830747435 CMS
Alnylam Pharmaceuticals Inc. $15.1804/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828518513 CMS
Janssen Pharmaceuticals, Inc $11.8404/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788215961 CMS
AbbVie Inc. $16.3804/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794763757 CMS
AstraZeneca Pharmaceuticals LP $14.8504/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829969629 CMS
PFIZER INC. $15.9403/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833519419 CMS
AbbVie Inc. $13.9703/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794763753 CMS
PFIZER INC. $16.7703/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832633831 CMS
Novo Nordisk Inc $12.9103/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811459557 CMS
Merck Sharp & Dohme Corporation $13.3103/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848611295 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,690.67 154
PY2020 $2,265.65 140
PY2021 $1,894.42 129
PY2022 $1,535.12 104
PY2023 $1,334.38 77
PY2024 $1,635.97 96
PY2025 $3,027.69 83

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $728,944.08 209
PY2024 Recipient $14,481.00 4
PY2024 Principal investigator $1,113,532.79 43
PY2023 Recipient $1,786.58 5
PY2023 Principal investigator $757,362.96 58
PY2022 Recipient $26,861.00 5
PY2022 Principal investigator $547,518.21 75
PY2021 Recipient $84.15 1
PY2021 Principal investigator $671,018.24 71
PY2020 Recipient $1,459.90 3
PY2020 Principal investigator $585,105.54 100
PY2019 Recipient $2,793.81 2
PY2019 Principal investigator $448,660.93 65

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

209 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $837.00 12/31/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228735940
Principal investigator 1 Eli Lilly and Company $25,042.00 12/29/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187887956
Principal investigator 1 PFIZER INC. $5,762.00 12/24/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228736177
Principal investigator 1 PFIZER INC. $3,520.00 12/19/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228745708
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,150.00 12/17/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802540
Principal investigator 1 ModernaTX, Inc. $1,400.00 12/17/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011154
Principal investigator 1 ModernaTX, Inc. $1,000.00 12/17/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011160
Principal investigator 1 ModernaTX, Inc. $1,245.00 12/17/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011180
Principal investigator 1 ModernaTX, Inc. $1,430.00 12/17/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011196
Principal investigator 1 ModernaTX, Inc. $750.00 12/17/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011204
Principal investigator 1 PFIZER INC. $8,370.00 12/17/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228723958
Principal investigator 1 PFIZER INC. $25,110.00 12/16/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228735581
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,403.00 12/09/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802538
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 12/02/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220994547
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631061
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 12/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631063
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631065
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631067
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631069
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631071
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631073
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631099
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.00 12/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792659
Principal investigator 1 PFIZER INC. $904.50 11/27/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228728065
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,750.00 11/14/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians - Jacob Murphy Lane
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15,250.00 11/14/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians - Jacob Murphy Lane
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 11/14/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians - Jacob Murphy Lane
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508380
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,500.00 11/14/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians - Jacob Murphy Lane
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508384
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,976.00 11/13/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802536
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631049
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631051
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631053
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631055
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631057
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631059
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631095
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631097
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.00 11/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792657
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631101
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631103
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 10/22/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220792661
Principal investigator 1 Eli Lilly and Company $10,790.00 10/20/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA No dispute reported 06/30/2026 1187887954
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631037
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631039
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631041
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631043
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631045
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631047
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631091
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631093
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.00 10/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792655
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,550.00 10/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802534
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 09/24/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631031
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 09/24/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631033
Principal investigator 1 Boehringer Ingelheim International GmbH $27.60 09/24/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631035
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 09/24/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220994545
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,271.00 09/18/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802532
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/17/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792651
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,250.00 09/10/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220802592
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630999
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631001
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631003
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631005
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631007
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631025
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631085
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.00 09/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792653
Principal investigator 1 ModernaTX, Inc. $98.80 08/28/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011184
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 08/26/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631087
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631089
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,693.00 08/06/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802530
Principal investigator 1 PFIZER INC. $2,519.50 08/06/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228788598
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,600.00 08/05/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802528
Principal investigator 1 PFIZER INC. $672.80 08/05/2025 Non-covered Recipient Entity
Preferred primary Care Physicians Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228784276
Principal investigator 1 PFIZER INC. $289.92 08/04/2025 Non-covered Recipient Entity
Preferred Primary Care Phys
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228713276
Principal investigator 1 PFIZER INC. $131.75 08/04/2025 Non-covered Recipient Entity
Preferred Primary Care Phys
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228713471
Principal investigator 1 PFIZER INC. $757.50 08/04/2025 Non-covered Recipient Entity
Preferred Primary Care Phys
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228713476
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630989
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630991
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630993
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630995
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630997
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 08/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631019
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631023
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631083
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.00 08/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792649
Principal investigator 1 PFIZER INC. $3,412.80 07/29/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228713278
Principal investigator 1 PFIZER INC. $125.38 07/29/2025 Non-covered Recipient Entity
Preferred Clinical Research
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228747256
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 07/28/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631027
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 07/28/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631029
Principal investigator 1 PFIZER INC. $384.75 07/23/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228763657
Principal investigator 1 PFIZER INC. $2,100.00 07/18/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCEDAILY ORAL DANUGLIPRON IN ADULTS WITH OVERWEIGHT OR OBESITY No dispute reported 06/30/2026 1228709997
Principal investigator 1 PFIZER INC. $1,221.75 07/16/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228763022
Principal investigator 1 PFIZER INC. $7,060.50 07/11/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228781581
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631009
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631011
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631013
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631015
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631017
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631021
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 07/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631075
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631077
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 07/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631079
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 07/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631081
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.00 07/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792647
Principal investigator 1 ModernaTX, Inc. $2,223.00 06/27/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011182
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.00 06/26/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802526
Principal investigator 1 PFIZER INC. $26,831.75 06/21/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228775765
Principal investigator 1 ModernaTX, Inc. $16,450.20 06/18/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011158
Principal investigator 1 PFIZER INC. $21,621.60 06/06/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228722514
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630961
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630963
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630965
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630967
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630969
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630971
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630973
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.00 06/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792645
Principal investigator 1 ModernaTX, Inc. $6,876.48 05/28/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011168
Principal investigator 1 ModernaTX, Inc. $2,946.72 05/28/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011176
Principal investigator 1 ModernaTX, Inc. $25,342.20 05/28/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011178
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 05/27/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630983
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 05/27/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630985
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 05/27/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630987
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,267.00 05/09/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802524
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630949
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630951
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630953
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630955
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630957
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630959
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.00 05/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792643
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,500.00 05/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802518
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,040.00 05/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802520
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,200.00 05/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802522
Principal investigator 1 PFIZER INC. $37,994.90 04/29/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228797619
Principal investigator 1 ModernaTX, Inc. $2,223.00 04/28/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011172
Principal investigator 1 ModernaTX, Inc. $7,074.08 04/28/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011190
Principal investigator 1 ModernaTX, Inc. $5,446.36 04/28/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011192
Principal investigator 1 ModernaTX, Inc. $1,473.36 04/28/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011198
Principal investigator 1 Eli Lilly and Company $111.39 04/24/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187887992
Principal investigator 1 Boehringer Ingelheim International GmbH $399.60 04/23/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630975
Principal investigator 1 Boehringer Ingelheim International GmbH $1,095.00 04/23/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630977
Principal investigator 1 Boehringer Ingelheim International GmbH $27.84 04/23/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630979
Principal investigator 1 Boehringer Ingelheim International GmbH $55.20 04/23/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630981
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,458.00 04/11/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802516
Principal investigator 1 PFIZER INC. $24,833.75 04/10/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228800034
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630937
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630939
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630941
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630943
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630945
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630947
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.00 04/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792641
Principal investigator 1 PFIZER INC. $1,421.55 04/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228779621
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,389.00 03/26/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802514
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 03/25/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630933
Principal investigator 1 Eli Lilly and Company $21,743.00 03/24/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA No dispute reported 06/30/2026 1187887888
Principal investigator 1 ModernaTX, Inc. $2,946.72 03/24/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011156
Principal investigator 1 ModernaTX, Inc. $6,738.16 03/24/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011164
Principal investigator 1 ModernaTX, Inc. $3,112.20 03/24/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011174
Principal investigator 1 Eli Lilly and Company $11.16 03/06/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES No dispute reported 06/30/2026 1187888692
Principal investigator 1 PFIZER INC. $1,500.00 03/04/2025 Non-covered Recipient Entity
Preferred primary Care Physicians Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228789489
Principal investigator 1 Eli Lilly and Company $9,900.00 03/03/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187887886
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630921
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630923
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630925
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630927
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630929
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630931
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.00 03/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792639
Principal investigator 1 PFIZER INC. $14,500.00 03/01/2025 Non-covered Recipient Entity
Preferred primary Care Physicians Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228787533
Principal investigator 1 ModernaTX, Inc. $17,784.00 02/27/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011162
Principal investigator 1 ModernaTX, Inc. $2,124.20 02/27/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011170
Principal investigator 1 ModernaTX, Inc. $7,350.72 02/27/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011194
Principal investigator 1 PFIZER INC. $2,058.75 02/19/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228711210
Principal investigator 1 Eli Lilly and Company $14,940.00 02/04/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES No dispute reported 06/30/2026 1187887554
Principal investigator 1 Eli Lilly and Company $20,702.00 02/04/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187887952
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630905
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630907
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630909
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630911
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630913
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630915
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 02/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630917
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 02/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630919
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.00 02/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792637
Principal investigator 1 Eli Lilly and Company $570.00 01/31/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187887558
Principal investigator 1 Eli Lilly and Company $325.00 01/31/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187888146
Principal investigator 1 Eli Lilly and Company $819.23 01/31/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187888696
Principal investigator 1 ModernaTX, Inc. $5,304.00 01/30/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011166
Principal investigator 1 PFIZER INC. $837.00 01/29/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228799474
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,853.00 01/28/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802512
Principal investigator 1 ModernaTX, Inc. $889.20 01/27/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011186
Principal investigator 1 ModernaTX, Inc. $7,434.70 01/27/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011188
Principal investigator 1 ModernaTX, Inc. $7,410.00 01/27/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011200
Principal investigator 1 ModernaTX, Inc. $2,946.72 01/27/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011202
Principal investigator 1 Eli Lilly and Company $57,000.00 01/21/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187887948
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,623.00 01/17/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802508
Principal investigator 1 PFIZER INC. $1,000.00 01/15/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228798572
Principal investigator 1 PFIZER INC. $29,252.75 01/09/2025 Non-covered Recipient Entity
Preferred Primary Care Physcians Inc
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228720631
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 01/06/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Inc Admin Office
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220802510
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630895
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630897
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630899
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630901
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630903
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220630935
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.00 01/01/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792635